Jonathan Yeh

Jonathan Yeh is a seasoned venture capital professional and biomedical entrepreneur with significant experience in investment and business development in the healthcare sector. Currently serving as Managing Partner at Saisei Ventures since November 2020, Jonathan focuses on investing in early-stage companies that aim to enhance health outcomes. As Co-Founder and Board Observer at Kenai Therapeutics, Jonathan is involved in developing Induced Pluripotent Stem Cell-based therapies for neurological diseases. Previously, Jonathan held key positions including Vice President of Investments at 株式会社ヘリオス, Director of Venture Investment at CCRM, Senior Advisor for Business Development at IRICoR, and Executive Director of the Leucegene Project. Jonathan completed a PhD in Experimental Medicine from McGill University and holds an MBA from Concordia University, as well as a Bachelor of Science in Microbiology and Immunology from McGill University.